Monoclonal antibody 2E1
Latest Information Update: 09 Aug 2002
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Johnson & Johnson Pharmaceutical Research & Development LLC
- Class Monoclonal antibodies
- Mechanism of Action Effector cell protease receptor-1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Graft-versus-host disease
Most Recent Events
- 17 May 1996 Preclinical development for Graft-versus-host disease in USA (Unknown route)